Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression.
Ladostigil is a novel drug that inhibits acetyl and butyrylcholinesterase, and monoamine oxidase (MAO) A and B selectively in the brain. It reverses memory deficits induced by chronic inhibition of cortical cytochrome oxidase in rats and has anxiolytic and antidepressant-like activity in prenatally-stressed rats. Ladostigil also prevents oxidative-nitrative stress induced in astrocytes in the hippocampal CA1 region following icv injection of STZ in rats which also impairs their episodic memory. The unique combination of ChE and MAO enzyme inhibition combined with neuroprotection makes ladostigil a potentially useful drug for the treatment of dementia in subjects that also have extrapyramidal dysfunction and depression.
Weinstock
M
M
Department of Pharmacology, Hebrew University Hadassah School of Medicine, Jerusalem, Israel. martar@md.huji.ac.il
Luques
L
L
Bejar
C
C
Shoham
S
S
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003704:Dementia / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*
C423264:(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002800:Cholinesterase Inhibitors; D007189:Indans; D008996:Monoamine Oxidase Inhibitors